Vaccinex, Inc. Files 8-K: Material Agreement, Equity Sales, Bylaw Changes
Ticker: VCNX · Form: 8-K · Filed: Apr 1, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2024 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 14 min |
| Key Dollar Amounts | $0.0001, $7.77, $1.5 million, $7.64, $140,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, corporate-action
TL;DR
Vaccinex filed an 8-K detailing a new material agreement, equity sales, and bylaw changes. Major corporate activity underway.
AI Summary
On March 27, 2024, Vaccinex, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and amendments to its articles of incorporation or bylaws. Financial statements and exhibits were also filed as part of this report.
Why It Matters
This 8-K filing indicates significant corporate actions by Vaccinex, Inc., including a new material agreement and changes to its corporate structure, which could impact its business operations and shareholder value.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and regulatory risks.
Key Players & Entities
- Vaccinex, Inc. (company) — Registrant
- March 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1895 Mount Hope Avenue, Rochester, New York 14620 (address) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Vaccinex, Inc. on March 27, 2024?
The filing indicates a material definitive agreement was entered into, but the specific details of this agreement are not provided in the provided text.
What type of equity securities were sold in the unregistered sales reported by Vaccinex, Inc.?
The filing mentions unregistered sales of equity securities, but the specific type and amount are not detailed in the provided text.
What specific amendments were made to Vaccinex, Inc.'s articles of incorporation or bylaws?
The filing states that amendments to articles of incorporation or bylaws were made, but the exact nature of these amendments is not specified in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on March 27, 2024.
What is Vaccinex, Inc.'s principal executive office address?
Vaccinex, Inc.'s principal executive office is located at 1895 Mount Hope Avenue, Rochester, New York 14620.
Filing Stats: 3,431 words · 14 min read · ~11 pages · Grade level 14.5 · Accepted 2024-04-01 17:04:32
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
- $7.77 — rrants were sold at a combined price of $7.77 per RDO Share and accompanying PIPE War
- $1.5 million — gregate gross proceeds of approximately $1.5 million. Each PIPE Warrant has an initial exe
- $7.64 — has an initial exercise price equal to $7.64 per share, is immediately exercisable,
- $140,000 — e Financial Advisor a cash fee equal to $140,000 and to reimburse the Financial Advisor
- $75,000 — tion with the Offering in the amount of $75,000. 1 The descriptions of the terms an
- $1.25 million — roceeds to the Company of approximately $1.25 million. Each Private Placement Warrant has a
- $1.75 million — ities") for aggregate gross proceeds of $1.75 million. The Company sold the ADDF Securities p
- $1.0 million — tedness for borrowed money in excess of $1.0 million. The Series A Preferred Stock is subjec
- $0.001 — y Series A Preferred Stock, par value $0.001 per share. Ranking, with respect to r
- $175,000 — nd winding up. Original Issue Price $175,000 per share of Series A Preferred Stock.
Filing Documents
- d801492d8k.htm (8-K) — 56KB
- d801492dex31.htm (EX-3.1) — 67KB
- d801492dex41.htm (EX-4.1) — 93KB
- d801492dex42.htm (EX-4.2) — 96KB
- d801492dex43.htm (EX-4.3) — 78KB
- d801492dex101.htm (EX-10.1) — 200KB
- d801492dex102.htm (EX-10.2) — 144KB
- d801492dex103.htm (EX-10.3) — 144KB
- d801492dex104.htm (EX-10.4) — 82KB
- 0001193125-24-083568.txt ( ) — 1352KB
- vcnx-20240327.xsd (EX-101.SCH) — 3KB
- vcnx-20240327_lab.xml (EX-101.LAB) — 18KB
- vcnx-20240327_pre.xml (EX-101.PRE) — 11KB
- d801492d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. The following exhibits are filed herewith: Exhibit Number Exhibit Description 3.1 Certificate of Designation of Series A Preferred Stock 5 4.1 Form of Common Stock Purchase Warrant for the AGP Transactions, dated March 28, 2024 4.2 Form of Common Stock Purchase Warrant for Private Placement, dated March 28, 2024 4.3 Common Stock Purchase Warrant issued to Alzheimer's Drug Discovery Foundation, dated March 29, 2024 10.1 Form of Securities Purchase Agreement for the AGP Transactions, by and between the Company and each purchaser identified on the signature pages thereto, dated as of March 27, 2024 10.2 Form of Securities Purchase Agreement for the Additional Private Placement, by and between the Company and each purchaser identified on the signature pages thereto, dated as of March 27, 2024 10.3 Securities Purchase Agreement, by and between the Company and Alzheimer's Drug Discovery Foundation, dated as of March 29, 2024 10.4 Registration Rights Agreement, by and between the Company and Alzheimer's Drug Discovery Foundation, dated as of March 29, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 6
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Vaccinex, Inc. Date: April 1, 2024 By: /s/ Maurice Zauderer Maurice Zauderer Chief Executive Officer